| Literature DB >> 22544182 |
M R Jordan1, D E Bennett, M A Wainberg, D Havlir, S Hammer, C Yang, L Morris, M Peeters, A M Wensing, N Parkin, J B Nachega, A Phillips, A De Luca, E Geng, A Calmy, E Raizes, P Sandstrom, C P Archibald, J Perriëns, C M McClure, S Y Hong, J H McMahon, N Dedes, D Sutherland, S Bertagnolio.
Abstract
The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22544182 PMCID： PMC3338313 DOI： 10.1093/cid/cis206
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079